Association of essential thrombocythemia and chronic lymphocytic leukemia: Absence of the V617F JAK2 mutation in the lymphoid compartment [8]

American Journal of Hematology

Volumn 82, Issue 6, 2007, Pages 500-501

  Henry, Laurent ^a   Carillo, Serge ^a   Jourdan, Eric ^a   Arnaud, Anne ^a   Brun, Sophie ^a   Lavabre Bertrand, Thierry ^a  

^a NÎMES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; JANUS KINASE 2;

ADULT; BONE MARROW BIOPSY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; ERYTHROMELALGIA; FEMALE; GENE MUTATION; HUMAN; LETTER; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; THROMBOCYTHEMIA;

FEMALE; HUMANS; HYDROXYUREA; JANUS KINASE 2; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; POINT MUTATION; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 34249796100     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20870     Document Type: Letter

References (6)

1. Vainchenker W, Constantinescu SN. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematol Am Soc Hematol Educ Prog 2005:195-200.
2. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005;106:3377-3379.
3. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hematopoietic cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006;108:3128-3134.
4. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood 2006;108:3548-3555.
5. V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders. Am J Hematol 2006;81:806-807.
6. Baxter EJ, Scott LM, Campbell PJ, et al. Aquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.